Stamet Tablet 50/1000 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dong Sung Pharmaceutical Co., Ltd.
MFDS item code 201505857 · Approved 2015.08.20
This product's status changed to Expired on 2025.08.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used by patients with type 2 diabetes to improve their blood sugar control. The combination of sitagliptin and metformin acts together to effectively lower blood sugar that is difficult to control with diet and exercise alone. This helps reduce the risk of complications and assists in maintaining healthy blood sugar levels. Patients should strictly adhere to their doctor's guidance and maintain diet and exercise alongside medication.
The dose of this drug for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Be Given This Drug). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Be Given This Drug).
This medication contains sitagliptin and metformin and is used for diabetes treatment. Firstly, serious allergic reactions may occur while taking this medication, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck appear, you should immediately stop taking the medication and inform your healthcare provider. Additionally, rare side effects such as pancreatitis (inflammation of the pancreas) have been reported, so if sudden abdominal pain, nausea, vomiting, or fever occurs, consult your doctor immediately. Metformin, included in this medication, can cause a rare but fatal metabolic condition known as lactic acidosis, so it should not be used in cases of severe dehydration, infections, heart disease, liver disease, or impaired kidney function. Particularly, if kidney function is moderately impaired or you are undergoing tests involving iodine contrast agents, you should discontinue this medication and restart it only after kidney function has recovered. This medication should not be used in pregnant or breastfeeding women, type 1 diabetes patients, or patients with acute metabolic acidosis. Be cautious as hypoglycemia may occur due to irregular eating habits, excessive exercise, or interactions with other medications, and the risk of hypoglycemia may increase when used in combination with insulin or sulfonylureas. Regular kidney function and blood tests should be conducted while on this medication, as vitamin B12 deficiency may occur and needs monitoring. If you are scheduled for surgery or have severe infections or trauma, temporarily discontinue use and resume after stabilization. Finally, alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided during treatment, and any discomfort experienced should be consulted with your healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air from entering, and it is advisable to keep it at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the drug's effectiveness and prevents deterioration.
Dark red oval film-coated tablet
56 tablets (14 tablets/PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dong Sung Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.